Thermo Fisher Scientific sets sights on Qiagen acquisition

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/Peskhova)
(Image: Getty/Peskhova)

Related tags: Thermo fisher, Technology, Laboratory, acquisition

The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.

The corporate leaderships of Thermo Fisher Scientific and Qiagen NV have mutually approved the proposal to snap up the purchased company for $44.54 (£29.68) per share. The total value of the transaction stands at approximately $11.5bn (€10.1bn), including assumption of about $1.5bn (€1.3bn) of net debt.

Ron O’Brien, Thermo Fisher Scientific’s senior director, told Outsourcing-Pharma that his company’s global reach and structure will enable the benefits of Qiagen’s technology and capabilities to reach more organizations around the world.

This will ultimately benefit the Qiagen business, because Thermo Fisher has a way of doing things that tend to make the business operate more efficiently​,” he said.

Qiagen provides a range of life-science and molecular diagnostic technologies. Its staff includes about 5,100 employees at 35 sites in more than 25 countries. Its 2019 revenue was more than $1.5bn.

Thermo Fisher Scientific chairman, president and CEO Marc Casper said the company offers the company a chance to “advance our customers' important work.”

“This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs​,” he said.

The company’s sample preparation technologies are employed to extract, isolate and purify DNA, RNA and proteins from biological samples. Its assay technologies are used to make biomolecules accessible for analysis.

Thierry Bernard—Qiagen’s interim CEO, senior vice president and head of the molecular diagnostics business area—said the company’s mission of “making improvements in life possible​” will continue under Thermo Fisher’s ownership.

"This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact​,” he said.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars